Dr. Monica Herrera
HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), today announced that Dr. Monica Herrera, MD, Bio-Rad Director R&D, Molecular Diagnostics, will chair a panel session during the Precision Medicine World Conference (PMWC) virtual event, “21st Century Precision Medicine in the Age of COVID-19,” held January 25–27. The panel session, “Development of New SARS-CoV-2 Therapeutics,” will take place on January 26 at 11:30 AM (PST).
The focus of the panel session will address the current therapeutic landscape of SARS-CoV-2, the virus associated with COVID-19, and how the pandemic is in many ways transforming global medical research. The panel will include four subsections that delve into specific therapeutic areas including: prophylaxis, repurposed antiviral agents, convalescent plasma therapy, and novel uses for anti-inflammatory compounds.
“Although vaccines with Emergency Use Authorization from the FDA are currently being distributed globally, this shouldn’t detract from the very important role therapeutics will continue to play in the fight against COVID-19,” Dr. Herrera said. “In this session, we will discuss the current therapeutic landscape for this virus and how this pandemic is transforming global medical research in many ways.”
Dr. Herrera develops assays for a variety of human genetics and infectious disease markets using Bio-Rad’s Droplet Digital PCR (ddPCR) technology.
Other session panelists will include:
- Dr. Aashish Manglik, MD, PhD, University of California, San Francisco
- Dr. Danielle Swaney, PhD, University of California, San Francisco
- Dr. Steven Quay, MD, PhD, Atossa Therapeutics, Inc.
- Dr. Anu Osinusi, MD, MPH, Gilead Sciences
- Dr. Peter Marks, MD, PhD, the United States Food and Drug Administration (FDA)
- Dr. Aaron Tobian, MD, PhD, The Johns Hopkins University School of Medicine
- Dr. Maximilian Konig, MD, The Johns Hopkins University School of Medicine
- Dr. Bruce Patterson, MD, IncellDx
Please register to attend the “21st Century Precision Medicine in the Age of COVID-19” event.
BIO-RAD, DDPCR, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
510-724-7000
tina_cuccia@bio-rad.com
CG Life
Ben Marcus
847-302-8430
bmarcus@cglife.com